ARCHIVES

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

Program Monitors Resistance In Antimicrobial And Antifungal Therapies for Cancer Patients

November 29, 2002

Oral Capecitabine Equal To 5FU-Leucovorin In Adjuvant Stage III Colon Cancer Treatment

June 25, 2004

Senate Calls Cancer Research a Priority, Cites Research Task Force Funding Goal

October 8, 1999

ONS Urges Congress To Back Anti-Tobacco Measures.

July 20, 2001

Natcher Subcommittee Open Door To justification for Increasing Cancer Program 1982 Appropriation

April 3, 1981

Amazon Links To NCI Materials, A First For NIH Health Content.

July 14, 2000